scholarly journals Less discontinuation of ADHD drug use since the availability of long-acting ADHD medication in children, adolescents and adults under the age of 45 years in the Netherlands

2010 ◽  
Vol 2 (4) ◽  
pp. 213-220 ◽  
Author(s):  
Els van den Ban ◽  
Patrick C. Souverein ◽  
Hanna Swaab ◽  
Herman van Engeland ◽  
Toine C. G. Egberts ◽  
...  
Keyword(s):  
Drug Use ◽  
The Netherlands ◽  
Adhd Medication ◽  
Adolescents And Adults ◽  
Long Acting

scholarly journals Cost-effectiveness of the fixed-dose combination tiotropium/olodaterol versus tiotropium monotherapy or a fixed-dose combination of long-acting β2-agonist/inhaled corticosteroid for COPD in Finland, Sweden and the Netherlands: a model-based study

BMJ Open ◽  
2021 ◽  
Vol 11 (8) ◽  
pp. e049675
Author(s):  
Martine Hoogendoorn ◽  
Isaac Corro Ramos ◽  
Stéphane Soulard ◽  
Jennifer Cook ◽  
Erkki Soini ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
The Netherlands ◽  
Cost Effective ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Inhaled Corticosteroid ◽  
Dose Combination ◽  
Long Acting ◽  
Β2 Agonist ◽  
Country Specific

ObjectivesChronic obstructive pulmonary disease (COPD) guidelines advocate treatment with combinations of long-acting bronchodilators for patients with COPD who have persistent symptoms or continue to have exacerbations while using a single bronchodilator. This study assessed the cost-utility of the fixed dose combination of the bronchodilators tiotropium and olodaterol versus two comparators, tiotropium monotherapy and long-acting β2 agonist/inhaled corticosteroid (LABA/ICS) combinations, in three European countries: Finland, Sweden and the Netherlands.MethodsA previously published COPD patient-level discrete event simulation model was updated with most recent evidence to estimate lifetime quality-adjusted life years (QALYs) and costs for COPD patients receiving either tiotropium/olodaterol, tiotropium monotherapy or LABA/ICS. Treatment efficacy covered impact on trough forced expiratory volume in 1 s (FEV1), total and severe exacerbations and pneumonias. The unit costs of medication, maintenance treatment, exacerbations and pneumonias were obtained for each country. The country-specific analyses adhered to the Finnish, Swedish and Dutch pharmacoeconomic guidelines, respectively.ResultsTreatment with tiotropium/olodaterol gained QALYs ranging from 0.09 (Finland and Sweden) to 0.11 (the Netherlands) versus tiotropium and 0.23 (Finland and Sweden) to 0.28 (the Netherlands) versus LABA/ICS. The Finnish payer’s incremental cost-effectiveness ratio (ICER) of tiotropium/olodaterol was €11 000/QALY versus tiotropium and dominant versus LABA/ICS. The Swedish ICERs were €6200/QALY and dominant, respectively (societal perspective). The Dutch ICERs were €14 400 and €9200, respectively (societal perspective). The probability that tiotropium/olodaterol was cost-effective compared with tiotropium at the country-specific (unofficial) threshold values for the maximum willingness to pay for a QALY was 84% for Finland, 98% for Sweden and 99% for the Netherlands. Compared with LABA/ICS, this probability was 100% for all three countries.ConclusionsBased on the simulations, tiotropium/olodaterol is a cost-effective treatment option versus tiotropium or LABA/ICS in all three countries. In both Finland and Sweden, tiotropium/olodaterol is more effective and cost saving (ie, dominant) in comparison with LABA/ICS.

Differences in ADHD medication usage patterns in children and adolescents from different cultural backgrounds in the Netherlands

2015 ◽  
Vol 50 (7) ◽  
pp. 1153-1162 ◽  
Author(s):  
Els F. van den Ban ◽  
Patrick C. Souverein ◽  
Herman van Engeland ◽  
Hanna Swaab ◽  
Toine C. G. Egberts ◽  
...  
Keyword(s):  
The Netherlands ◽  
Children And Adolescents ◽  
Adhd Medication ◽  
Cultural Backgrounds ◽  
Medication Usage ◽  
Usage Patterns

scholarly journals Developmental approaches to substance use and abuse

1999 ◽  
Vol 11 (4) ◽  
pp. 655-656 ◽  
Author(s):  
DANTE CICCHETTI ◽  
SUNIYA S. LUTHAR
Keyword(s):  
Drug Use ◽  
Protective Factors ◽  
Developmental Psychopathology ◽  
Developmental Stages ◽  
Risk And Protective Factors ◽  
Institute Of Medicine ◽  
Drug Use Disorders ◽  
Adolescents And Adults

In 1996 the Institute of Medicine (IOM, 1996) issued a report on pathways to addiction. Although focused on the use of illegal drugs, the recommendations of the committee are equally applicable to more socially condoned, but still addictive, substances such as alcohol. The IOM (1996) report articulated the types of research that would be needed to expand the understanding of the etiology of drug use disorders, including the following: (a) multidisciplinary research to investigate the combined effects of biological, psychosocial, and contextual factors as they relate to the development of drug use, abuse, and dependence; (b) studies of sufficient duration to enable follow-up of participants in determining the role of risk and protective factors related to the transition from drug use to abuse to dependence; (c) research investigating the role of family factors in the etiology of drug use and abuse; (d) examination of psychopathology as a precursor to drug use and abuse in adolescents and adults; (e) studies of risk and protective factors related to drug use and abuse, especially during discrete developmental stages; and (f) investigation of childhood risk and protective factors that are associated with drug abuse and dependence. In reflecting on these comprehensive goals, striking similarities emerge with respect to these research foci and the field of developmental psychopathology (Cicchetti & Cohen, 1995; Cicchetti & Toth, 1991). Specifically, the principles that guide inquiries conceptualized within a developmental psychopathology framework can be applied toward the conduct of studies designed to address the agenda generated by the IOM (1996) report on substance abuse.

Pharmacology of Adult ADHD with Stimulants

CNS Spectrums ◽  
2007 ◽  
Vol 12 (S6) ◽  
pp. 8-11 ◽  
Author(s):  
Thomas J. Spencer
Keyword(s):  
Primary Care Physicians ◽  
Adult Adhd ◽  
Brain Disorder ◽  
Stimulant Treatment ◽  
Children With Adhd ◽  
Adolescents And Adults ◽  
Stimulant Medications ◽  
Long Acting ◽  
Core Symptoms ◽  
The Brain

AbstractAttention-deficit/hyperactivity disorder (ADHD) is a lifelong condition that begins in childhood and continues with adult manifestations related to the core symptoms. Approximately 50% to 75% of children with ADHD continue to meet criteria for the disorder as adolescents and adults. Adults with the disorder increasingly present to primary care physicians, psychiatrists, and other practitioners for diagnosis and treatment. Understanding the diagnosis of ADHD in adults requires knowledge of age-dependent decline of symptoms over time. Retrospective recall of symptoms and impairment are valid methods of diagnosing the disorder. ADHD is also a brain disorder with a strong neurobiologic basis, complex etiology, and genetic component. Genetic and environmental vulnerabilities give rise to abnormalities in the brain and subsequent behavioral and cognitive deficits, which may produce the symptoms associated with ADHD. Magnetic resonance imaging studies of ADHD have provided evidence that abnormalities in the brain are caused by the disorder itself rather than treatment of the disorder. Psychiatric comorbidity is common among patients with ADHD and tends to complicate treatment. Acute and long-term use of long-acting stimulant formulations (methylphenidate and amphetamine compounds) have shown robust efficacy and tolerability consistent with the treatment response established in children with ADHD. Non-stimulant medications have demonstrated efficacy as well, and may be preferred in patients with tic and substance use disorders.In this expert roundtable supplement, Timothy E. Wilens, MD, reviews the epidemiology and clinical presentation of adult ADHD. Next, Joseph Biederman, MD, provides an overview of recent advances in the neurobiology of ADHD. Thomas J. Spencer, MD, reviews stimulant treatment of adult ADHD, and Lenard A. Adler concludes with a discussion of non-stimulant trials in adult ADHD.

scholarly journals PMH17 COST-EFFECTIVENESS OF LONG ACTING METHYLPHENIDATE-OROS IN ADHD YOUTHS WITH SUBOPTIMAL SYMPTOM CONTROL ON IMMEDIATE-RELEASE METHYLPHENIDATE IN THE NETHERLANDS

2006 ◽  
Vol 9 (6) ◽  
pp. A314-A315 ◽  
Author(s):  
A Faber ◽  
M Van Agthoven ◽  
L Kalverdijk ◽  
H Tobi ◽  
L De Jong van den Berg ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
The Netherlands ◽  
Symptom Control ◽  
Immediate Release ◽  
Long Acting

Practical feasibility of outcomes research in oncology: Lessons learned in assessing drug use and cost-effectiveness in The Netherlands

2013 ◽  
Vol 49 (1) ◽  
pp. 8-16 ◽  
Author(s):  
Margreet G. Franken ◽  
Chantal W.M. van Gils ◽  
Jennifer G. Gaultney ◽  
Gepke O. Delwel ◽  
Wim Goettsch ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Drug Use ◽  
The Netherlands ◽  
Outcomes Research ◽  
Lessons Learned ◽  
Practical Feasibility

Panel Discussion

CNS Spectrums ◽  
2007 ◽  
Vol 12 (S6) ◽  
pp. 14-14 ◽  
Keyword(s):  
Primary Care Physicians ◽  
Adult Adhd ◽  
Panel Discussion ◽  
Brain Disorder ◽  
Stimulant Treatment ◽  
Children With Adhd ◽  
Adolescents And Adults ◽  
Stimulant Medications ◽  
Long Acting ◽  
The Brain

AbstractAttention-deficit/hyperactivity disorder (ADHD) is a lifelong condition that begins in childhood and continues with adult manifestations related to the core symptoms. Approximately 50% to 75% of children with ADHD continue to meet criteria for the disorder as adolescents and adults. Adults with the disorder increasingly present to primary care physicians, psychiatrists, and other practitioners for diagnosis and treatment. Understanding the diagnosis of ADHD in adults requires knowledge of age-dependent decline of symptoms over time. Retrospective recall of symptoms and impairment are valid methods of diagnosing the disorder. ADHD is also a brain disorder with a strong neurobiologic basis, complex etiology, and genetic component. Genetic and environmental vulnerabilities give rise to abnormalities in the brain and subsequent behavioral and cognitive deficits, which may produce the symptoms associated with ADHD. Magnetic resonance imaging studies of ADHD have provided evidence that abnormalities in the brain are caused by the disorder itself rather than treatment of the disorder. Psychiatric comorbidity is common among patients with ADHD and tends to complicate treatment. Acute and long-term use of long-acting stimulant formulations (methylphenidate and amphetamine compounds) have shown robust efficacy and tolerability consistent with the treatment response established in children with ADHD. Non-stimulant medications have demonstrated efficacy as well, and may be preferred in patients with tic and substance use disorders.In this expert roundtable supplement, Timothy E. Wilens, MD, reviews the epidemiology and clinical presentation of adult ADHD. Next, Joseph Biederman, MD, provides an overview of recent advances in the neurobiology of ADHD. Thomas J. Spencer, MD, reviews stimulant treatment of adult ADHD, and Lenard A. Adler concludes with a discussion of non-stimulant trials in adult ADHD.

Sign in / Sign up

Export Citation Format

Share Document